Drug Trial Radar · NCT06902376
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Jun 3, 2025
Primary completion
Mar 31, 2028
Study completion Aug 31, 2028
Sponsor
- Lead sponsor
- UNC Lineberger Comprehensive Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Regeneron Pharmaceuticals; Exelixis
- First posted
- Mar 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants with wild-type (WT) anaplastic thyroid cancer (ATC) that has a BRAF mutation (BRAF V600E).
Conditions
- Anaplastic Thyroid Cancer
- Thyroid Cancer
- BRAF Mutation-Related Tumors
Interventions
CemiplimabBiological
Cemiplimab will be administered at a dose of 350mg intravenous over 30 minutes every 3 weeks for 3 cycles (cycle length is 21 days) at weeks 1, 4, and 7.
XL092Drug
XL092 will be administered at a dose of 60mg PO daily for 8 weeks (weeks 1-8)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete gross resectionTime frame: 12 weeks
- Non-hematologic treatment related adverse events (TRAEs)Time frame: Up to 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Dana Farber/Harvard Cancer Center
Boston, Massachusetts · Not yet recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.